These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 1588766)
1. [Protective effect by piperacillin against renal impairment caused by amikacin]. Kusafuka H; Obayashi T; Iwayama N; Sezaki R; Izuhara Y; Yoshida H; Goto M; Maeda K Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):153-62. PubMed ID: 1588766 [TBL] [Abstract][Full Text] [Related]
2. [Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study]. Sampi K; Hattori M Gan To Kagaku Ryoho; 1992 Aug; 19(9):1315-20. PubMed ID: 1503486 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of synergistic enhancement of antimicrobial activities of piperacillin and amikacin against Pseudomonas aeruginosa using FIC index and disc diffusion method]. Uete T; Matsuo K Jpn J Antibiot; 1990 Sep; 43(9):1572-8. PubMed ID: 2124633 [TBL] [Abstract][Full Text] [Related]
4. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269 [TBL] [Abstract][Full Text] [Related]
6. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226 [TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin. Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878 [TBL] [Abstract][Full Text] [Related]
8. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044 [TBL] [Abstract][Full Text] [Related]
9. [In the search for effective and safe dose of amikacin in patients with chronic kidney disease]. Gomółka M; Szamotulska K; Rymarz A; Brodowska-Kania D; Dubchak I; Piechota W; Jurkiewicz D; Niemczyk S Pol Merkur Lekarski; 2014 Apr; 36(214):240-4. PubMed ID: 24868895 [TBL] [Abstract][Full Text] [Related]
10. Relationship between amikacin blood concentration and ototoxicity in low birth weight infants. Endo A; Nemoto A; Hanawa K; Maebayashi Y; Hasebe Y; Kobayashi M; Naito A; Kobayashi Y; Yamamoto S; Isobe K J Infect Chemother; 2019 Jan; 25(1):17-21. PubMed ID: 30539740 [TBL] [Abstract][Full Text] [Related]
11. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898 [TBL] [Abstract][Full Text] [Related]
12. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study. Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517 [TBL] [Abstract][Full Text] [Related]
13. Low serum albumin and the increased risk of amikacin nephrotoxicity. Contreras AM; Ramírez M; Cueva L; Alvarez S; de Loza R; Gamba G Rev Invest Clin; 1994; 46(1):37-43. PubMed ID: 8079062 [TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of combination therapy with cefoxitin and amikacin in complicated urinary tract infections]. Sakashita S; Shinno Y; Asano Y; Tubo S; Imanaka K; Miyabe N; Nagamori S; Takahashi Y; Koyanagi T Hinyokika Kiyo; 1986 Oct; 32(10):1547-50. PubMed ID: 3565192 [TBL] [Abstract][Full Text] [Related]
15. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration. Lanao JM; Dominguez-Gil A; Tabernero JM; Molina HD Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):271-5. PubMed ID: 7107075 [TBL] [Abstract][Full Text] [Related]
16. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510 [TBL] [Abstract][Full Text] [Related]
17. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Sweileh WM Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328 [TBL] [Abstract][Full Text] [Related]
18. [Study of the local use of amikacin]. Wada S; Nishio S; Kishimoto T; Maekawa M; Yuki K; Sasaki S; Oshima N; Hayahara N; Nishijima T; Funai K Hinyokika Kiyo; 1985 May; 31(5):907-13. PubMed ID: 4050636 [TBL] [Abstract][Full Text] [Related]
19. [Reevaluation of clinical efficacy of piperacillin against complicated urinary tract infections]. Ueno M; Ikeuchi T; Kai Y Hinyokika Kiyo; 1988 Sep; 34(9):1675-8. PubMed ID: 3213800 [TBL] [Abstract][Full Text] [Related]
20. Onset of Hemophagocytic Lymphohistiocytosis during Piperacillin-Tazobactam Therapy in Three Children with Acute Focal Bacterial Nephritis. Miyabayashi H; Kumaki S; Sato A; Onuma R; Noguchi R; Sato T; Metoki T; Watanabe Y; Tazawa Y; Imaizumi M; Kitaoka S Tohoku J Exp Med; 2018 May; 245(1):55-59. PubMed ID: 29798969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]